MedTrace Logo

Neurocognitive Assessment in Long-Term Survivors of Lymphoma

NCT07652476 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-06-22

No results posted yet for this study

Summary

This is an observational, multicenter, prospective cohort study including patients treated for lymphoma in Italian real-life. Patients eligible for the enrollment in the study will be consecutively included in Italian FIL centers. Patients will be evaluated once during regular follow-up, in the absence of clinical or radiologic signs of disease relapse.

The assessment of neurocognitive functioning will be performed through a panel of tests, both self-administered and individually administered (about 1 hour). The administration of these neuropsychological tests should be done according to a standardized and predefined order. If available, according to local practice, a neuropsychologist may be involved in test administration and in the evaluation of the results.

Based on its observational nature, no treatment change or modification or additional exams or visits will be required because of being enrolled in this study.

Conditions

  • Classic Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Primary Mediastinal B Cell Lymphoma

Interventions

DRUG

anthracycline containing regimen

Patients in complete remission after treatment with first line anthracycline containing regimen (ABVD, BV-AVD, BEACOPP, R-CHOP, Pola-R-CHP o R-DA-EPOCH) +/- radiotherapy.

Sponsors & Collaborators

  • Associazione Italiana contro Leucemie, Linfomi e Mieloma

    collaborator UNKNOWN

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Silvia Franceschetti · U.O.C. Ematologia Ospedale Civile di Legnano - ASST Ovest Milanese - Legnano

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07652476 on ClinicalTrials.gov